AQR reports 3.16M Haemonetics (HAE) shares in passive 13G filing

Rhea-AI Filing Summary

AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report a passive ownership stake in Haemonetics Corp3,163,104 shares of Haemonetics common stock, representing 6.76% of the class as of 12/31/2025.

The firms report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over all 3,163,104 shares. They certify the position was acquired and is held in the ordinary course of business, not to change or influence control of Haemonetics.

Insights

Equity ownership and governance analyst

AQR discloses a passive 6.76% stake in Haemonetics.

AQR Capital Management, LLC and its parent report beneficial ownership of 3,163,104 Haemonetics shares, equal to 6.76% of the common stock as of 12/31/2025. All voting and dispositive authority is reported as shared, with no sole control over the position.

The certification states the stake is held in the ordinary course of business and not for the purpose of changing or influencing control. This aligns with a Schedule 13G passive investment. Any future impact depends on changes in ownership level or filing status disclosed in subsequent reports.

02/13/2026 - 10:10 AM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

HAEMONETICS CORP

(Name of Issuer)

Common stock, $.01 par value per share

(Title of Class of Securities)

405024100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 405024100

1

Names of Reporting Persons

AQR Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,163,104.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,163,104.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,163,104.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.76 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 405024100

1

Names of Reporting Persons

AQR Capital Management Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,163,104.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,163,104.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,163,104.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.76 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: HAEMONETICS CORP
(b)	Address of issuer's principal executive offices: 125 SUMMER STREET, BOSTON, MASSACHUSETTS 02110
Item 2.
(a)	Name of person filing: AQR Capital Management, LLC AQR Capital Management Holdings, LLC
(b)	Address or principal business office or, if none, residence: ONE GREENWICH PLAZA SUITE 130 Greenwich, Connecticut 06830
(c)	Citizenship: AQR Capital Management, LLC - UNITED STATES AQR Capital Management Holdings, LLC - UNITED STATES
(d)	Title of class of securities: Common stock, $.01 par value per share
(e)	CUSIP No.: 405024100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,163,104
(b)	Percent of class: 6.76 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: AQR Capital Management, LLC - 0 AQR Capital Management Holdings, LLC - 0
	(ii) Shared power to vote or to direct the vote: AQR Capital Management, LLC - 3,163,104 AQR Capital Management Holdings, LLC - 3,163,104
	(iii) Sole power to dispose or to direct the disposition of: AQR Capital Management, LLC - 0 AQR Capital Management Holdings, LLC - 0
	(iv) Shared power to dispose or to direct the disposition of: AQR Capital Management, LLC - 3,163,104 AQR Capital Management Holdings, LLC - 3,163,104
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Item 2(a) above.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AQR Capital Management, LLC

Signature:	Henry Parkin
Name/Title:	Authorized Signatory
Date:	02/13/2026

AQR Capital Management Holdings, LLC

Signature:	Henry Parkin
Name/Title:	Authorized Signatory
Date:	02/13/2026

Exhibit Information

AQR Capital Management Holdings, LLC and AQR Capital Management, LLC hereby agree that this Schedule 13G is filed on behalf of each of the parties. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.

FAQ

What percentage of Haemonetics (HAE) shares does AQR Capital Management report owning?

AQR Capital Management and its parent report beneficial ownership of 6.76% of Haemonetics’ common stock, totaling 3,163,104 shares as of December 31, 2025. This stake gives them shared voting and shared dispositive power over all reported shares.

How many Haemonetics (HAE) shares are beneficially owned by AQR according to the Schedule 13G?

The filing reports that AQR Capital Management, LLC and AQR Capital Management Holdings, LLC beneficially own 3,163,104 shares of Haemonetics common stock. This amount represents 6.76% of the outstanding class as of December 31, 2025, with shared voting and dispositive power.

Is AQR’s ownership in Haemonetics (HAE) considered passive or for control purposes?

AQR certifies the Haemonetics stake is held in the ordinary course of business and not for changing or influencing control. The Schedule 13G states the securities were not acquired in connection with any transaction having that purpose or effect, indicating a passive investment posture.

Who are the reporting persons in the Haemonetics (HAE) Schedule 13G filing?

The Schedule 13G lists AQR Capital Management, LLC and AQR Capital Management Holdings, LLC as reporting persons. AQR Capital Management, LLC is described as a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and both are organized in the United States.

What voting and dispositive powers does AQR report over its Haemonetics (HAE) shares?

AQR reports no sole voting or dispositive power over Haemonetics shares. Instead, it discloses shared voting power and shared dispositive power over all 3,163,104 shares beneficially owned, consistent for both AQR Capital Management, LLC and its parent entity.

What key date is associated with AQR’s Haemonetics (HAE) ownership in this filing?

The Schedule 13G identifies December 31, 2025 as the date of event requiring the filing. As of this date, AQR Capital Management entities report beneficial ownership of 3,163,104 Haemonetics shares, representing 6.76% of the company’s common stock.